Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XNCR
SELLXencor, Inc. · Healthcare · United States · $1.4B · Avg Vol: $20M/d
COMPANY DESCRIPTION
Xencor, Inc. is a clinical-stage biotechnology company focused on developing engineered monoclonal antibodies for cancer and autoimmune diseases, utilizing its proprietary XmAb® technology platform. This platform provides a significant competitive moat by enabling the creation of antibodies with enhanced therapeutic functions and improved half-life. Xencor operates as a research-intensive biotech, often partnering with larger pharmaceutical companies to develop its innovative pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.6M | 174.6M | 110.5M | 125.6M | -8.6% | 97.4M | 70.6M | 110.5M | -6.2% |
| EPS | -0.93 | -2.08 | -3.58 | -1.24 | — | -2.46 | -4.03 | -3.55 | — |
| Shares | 60.0M | 61.0M | 70.3M | 71.9M | +19.8% | 74.1M | — | — | — |
| Debt | 59.6M | 251.9M | 232.0M | 187.7M | 46.6% | 175.2M | — | — | — |
| Equity | 727.5M | 661.8M | 677.6M | 635.6M | -4.4% | — | — | — | — |
| Op CF | 24.5M | -77.9M | -202.2M | -135.1M | — | -186.5M | — | — | — |
| Inv CF | -119.7M | -111.1M | -7.9M | 140.0M | — | — | — | — | — |
| Fin CF | 5.7M | 189.2M | 197.2M | 8.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XNCR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XNCR | Xencor, Inc.(you) | $1.4B | 30 | SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 29 | SELL |
| VIR | Vir Biotechnology, Inc. | $1.5B | 32 | SELL |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 30 | SELL |
| BCAX | Bicara Therapeutics Inc. | $1.8B | 31 | SELL |
| SEPN | Septerna, Inc. | $1.5B | 35 | HOLD |
| FBRX | Forte Biosciences, Inc. | $1.1B | 28 | SELL |
| JBIO | Jade Biosciences, Inc. | $1.2B | 33 | SELL |
| PVLA | Palvella Therapeutics, Inc. | $2.0B | 28 | SELL |
| MGTX | MeiraGTx Holdings plc | $1.1B | 32 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%